What's the most recent regulatory action in Inflammatory Disease of Female Pelvic Organs?

Most recent: Cleocin T — FDA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/inflammatory-disease-of-female-pelvic-organs.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Inflammatory Disease of Female Pelvic Organs — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Inflammatory Disease of Female Pelvic Organs (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Inflammatory Disease of Female Pelvic Organs, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Zosyn	TAZOBACTAM	Merck Sharp & Dohme B.V.	beta Lactamase Inhibitor		1993-01-01
Azactam	AZTREONAM	Bristol-Myers Squibb	Monobactam Antibacterial [EPC]		1986-01-01
Unasyn	SULBACTAM	Pfizer	beta Lactamase Inhibitor	Serine beta-lactamase-like protein LACTB, mitochondrial	1986-01-01
Primaxin	IMIPENEM	Merck Sharp & Dohme B.V.	imipenem		1985-01-01
Fortaz	Ceftazidime	Pai Holdings Pharm	Third-generation cephalosporin	Bacterial cell wall	1985-01-01
Primaxin	CILASTATIN	Merck & Co.	Renal Dehydropeptidase Inhibitor	Dipeptidase 1	1985-01-01
Rocephin	ceftriaxone	Generic (originally Roche)	Cephalosporin antibiotic (third-generation)	Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A	1984-12-21
Cleocin T	CLINDAMYCIN PHOSPHATE	Pfizer	Lincosamide Antibacterial		1972-01-01
Cleocin	clindamycin	Generic (originally Upjohn/Pfizer)	Lincosamide antibiotic	50S ribosomal protein L10	1970-01-01
Unasyn	AMPICILLIN	Bristol-Myers Squibb	Penicillin-class Antibacterial	Transient receptor potential cation channel subfamily M member 4	1965-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-03-23 — Cleocin T · FDA · approved · US
2026-03-18 — Cleocin T · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 5 drugs in Inflammatory Disease of Female Pelvic Organs
Bristol-Myers Squibb · 2 drugs in Inflammatory Disease of Female Pelvic Organs
Merck Sharp & Dohme B.V. · 2 drugs in Inflammatory Disease of Female Pelvic Organs
Pai Holdings Pharm · 2 drugs in Inflammatory Disease of Female Pelvic Organs
Pfizer · 2 drugs in Inflammatory Disease of Female Pelvic Organs
Merck & Co. · 1 drug in Inflammatory Disease of Female Pelvic Organs
Tel-Aviv Sourasky Medical Center · 1 drug in Inflammatory Disease of Female Pelvic Organs
Astellas Pharma · 1 drug in Inflammatory Disease of Female Pelvic Organs
Centre Hospitalier Universitaire Vaudois · 1 drug in Inflammatory Disease of Female Pelvic Organs
Generic (originally Roche) · 1 drug in Inflammatory Disease of Female Pelvic Organs
Generic (originally Upjohn/Pfizer) · 1 drug in Inflammatory Disease of Female Pelvic Organs

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Inflammatory Disease of Female Pelvic Organs:

Cite this brief

Drug Landscape (2026). Inflammatory Disease of Female Pelvic Organs — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/inflammatory-disease-of-female-pelvic-organs. Accessed 2026-06-10.

Inflammatory Disease of Female Pelvic Organs full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing